Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe.

ESMO open·2025
Same author

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.

Cancers·2023
Same author

Genetic variant in complement receptor 1 (CR1, CD35) is associated with a cluster of severe fatal COVID-19 in a family.

The Journal of infection·2023
Same author

Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer.

Cancers·2022
Same author

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.

Clinical epigenetics·2022
Same author

Evaluation of Monocarboxylate Transporter 4 (<i>MCT4)</i> Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.

Frontiers in cell and developmental biology·2021
Same journal

Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer.

Oncology reports·2026
Same journal

Research advances on DKK1 in head and neck squamous cell carcinoma: Linking molecular mechanisms to clinical applications (Review).

Oncology reports·2026
Same journal

PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.

Oncology reports·2026
Same journal

A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer.

Oncology reports·2026
Same journal

Sterol regulatory element‑binding proteins: Master regulators of lipid metabolic reprogramming in cancer and emerging therapeutic targets (Review).

Oncology reports·2026
Same journal

Dual targeting of mitochondrial metabolism and Rho GTPase signaling to suppress cancer metastasis (Review).

Oncology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Tamoxifen-induced hypertriglyceridaemia.

D Mikhailidis1, E Ganotakis, V Georgoulias

  • 1UNIV CRETE,GEN HOSP,SCH MED,DEPT CLIN ONCOL,IRAKLION 71110,CRETE,GREECE.

Oncology Reports
|May 19, 2011
PubMed
Summary
This summary is machine-generated.

Tamoxifen use can lead to hypertriglyceridemia, a condition of high triglycerides, potentially causing pancreatitis or heart disease. Monitoring triglyceride levels in patients on tamoxifen is crucial for early detection and management.

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jun 1, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Tamoxifen is a widely used medication for breast cancer treatment.
  • While generally improving lipid profiles, tamoxifen has been associated with elevated serum triglyceride levels in some studies.
  • Hypertriglyceridemia is a known risk factor for pancreatitis and cardiovascular events.

Purpose of the Study:

  • To report cases of breast adenocarcinoma patients who developed hypertriglyceridemia with tamoxifen use.
  • To highlight the potential for severe complications such as acute pancreatitis and increased ischemic heart disease risk.
  • To emphasize the importance of monitoring triglyceride levels in patients receiving tamoxifen therapy.

Main Methods:

  • Case series reporting on seven patients with breast adenocarcinoma.
  • Clinical observation of serum triglyceride levels before and after tamoxifen initiation.
  • Assessment of associated conditions like insulin resistance, diabetes, and apolipoprotein phenotype.
  • Evaluation of treatment efficacy with fibrates for hypertriglyceridemia.

Main Results:

  • Seven cases of breast adenocarcinoma with tamoxifen-associated hypertriglyceridemia were identified.
  • Two patients experienced life-threatening acute pancreatitis.
  • Two patients showed increased serum triglycerides after starting tamoxifen.
  • Five patients had coexisting insulin resistance or diabetes, potentially worsening hypertriglyceridemia.
  • Fibrates demonstrated effectiveness in reducing serum triglyceride levels.

Conclusions:

  • Tamoxifen use can precipitate or exacerbate hypertriglyceridemia in breast cancer patients.
  • Hypertriglyceridemia is a significant risk factor for acute pancreatitis and ischemic heart disease in this population.
  • Regular screening for hypertriglyceridemia is essential for patients on tamoxifen to prevent severe adverse events.